Profilo
Michael Wittekind worked as an Executive Director-Research at Amgen, Inc. from 2003 to 2007, an Associate Director at Bristol-Myers Squibb Pharmaceutical Research Institute, and a Chief Scientific Officer & Senior VP-Research at ContraFect Corp.
from 2014 to 2016.
He also worked as a Director-Process Development at Phylos, Inc. Dr. Wittekind holds a doctorate degree from the University of Wisconsin and a graduate degree from the University of Washington.
Precedenti posizioni note di Michael Wittekind
| Società | Posizione | Fine |
|---|---|---|
| CONTRAFECT CORPORATION | Direttore Tecnico/Scientifico/R&S | 01/10/2016 |
| AMGEN INC. | Direttore Tecnico/Scientifico/R&S | 01/11/2007 |
Bristol-Myers Squibb Pharmaceutical Research Institute | Corporate Officer/Principal | - |
Phylos, Inc.
Phylos, Inc. Miscellaneous Commercial ServicesCommercial Services Provides biopharmaceutical research and manufacturing services | Corporate Officer/Principal | - |
Formazione di Michael Wittekind
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 6 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
University of Washington
University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Phylos, Inc.
Phylos, Inc. Miscellaneous Commercial ServicesCommercial Services Provides biopharmaceutical research and manufacturing services | Commercial Services |
University of Wisconsin
University of Wisconsin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bristol-Myers Squibb Pharmaceutical Research Institute | |
ContraFect Corp.
ContraFect Corp. BiotechnologyHealth Technology Engages in discovery and development of direct lytic agents for life-threatening & drug-resistant infectious diseases | Health Technology |
















